Sense Neuro Diagnostics Joins MedTech Accelerator Third Cohort
The Mayo Clinic and ASU MedTech Accelerator, a flagship program of the Mayo Clinic and ASU Alliance for Health Care, launched their third cohort on March 28, 2022. Ohio’s Sense Neuro Diagnostics, has been selected as one of the eight participants.
The accelerator provides emerging companies with a multi-day immersive curriculum in health care entrepreneurship including: lectures and workshops with world-class scientific and engineering experts; resources to navigate regulatory pathways; and tools for product commercialization and customer acquisition. Additionally, participants attend mentoring, business development, and networking events.
Sense Neuro is developing non-invasive technology enabling rapid, comprehensive detection of stroke subtype + TBI, and continuous brain injury monitoring.
There is no accurate, objective way to detect stroke subtype or brain hemorrhage in a field environment or to monitor ongoing brain injury continuously, non-invasively and in real time. Without this real-time detection, patients must be transported to the closest equipped care facility for treatment, wasting the precious resource of time.
Sense Neuro has worked tirelessly to develop non-invasive brain scanners that can monitor this neurological status in real time. In fact, the system can scan the entire cranial vault in just 2.5 seconds using nine antennas which alternate between transmitting and receiving a safe, low-power radio frequency pulse across the brain. Healthy brain tissues have unique electrical properties that alter the RF wave as it passes through the tissue. Similarly, hemorrhages and ischemic tissue cause distinctive changes to the RF signal.
The company currently has three product pipelines. NeuSTAT, for continuous hospital monitoring, is available for investigational use. NeuroHawk Military and NeuroHawk ED/EMS are both still in development, striving to achieve a product for military use in the field and for rapid triage and assessment by paramedics. These development efforts will be aided by the support offered with the MedTech Accelerator.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.